Harrow Inc

Research Harrow Inc (HROW) on Bullrun: market cap USD 1.55B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 1.55B.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 272.30M-USD 5.14MUSD 42.98M75.1%-0.14USD 72.93MUSD 250.00MUSD 52.45M
FY2024USD 199.61M-USD 17.48M-USD 23.80M75.3%-0.49USD 47.25MUSD 262.74MUSD 69.65M
FY2023USD 130.19M-USD 24.41MUSD 2.38M69.6%-0.75USD 74.09MUSD 246.72MUSD 70.77M
FY2022USD 88.60M-USD 14.09M-USD 892.00K71.3%-0.51USD 96.27MUSD 151.77MUSD 27.60M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 1.55Bn/an/an/a
20252025-12-31USD 1.82Bn/an/an/a
20242024-12-31USD 1.20Bn/an/an/a
20232023-12-29USD 393.32Mn/an/an/a
20222022-12-30USD 439.70Mn/an/an/a
20212021-12-31USD 232.44Mn/an/an/a

About Harrow Inc

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Harrow Inc's market cap?

Harrow Inc's market capitalization is USD 1.55B.

What does Harrow Inc do?

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications.